Unlocking Digital Endpoints: A New Era in Trials
In the rapidly evolving world of clinical trials, digital endpoints are emerging as critical components that enhance the precision...
Navigating the Complexities of Cell and Gene Therapy Manufacturing
The 2024 DIA conference, a session about gene therapy manufacturing chaired by Dr. Fouad Atouf, Senior Vice President of...
AN2 Therapeutics Fails Phase 2 Lung Trial
After releasing unfavorable results from the Phase 2 portion of the EBO-301 study, AN2 Therapeutics has decided to cease...
Humanetics Corp Partnership: Advancing Radiation Countermeasures
Humanetics Corporation and researchers from the Armed Forces Radiobiology Research Institute (AFRRI) have partnered to secure $3 million in...
Paige Partners with Microsoft to Introduce AI Models for Cancer
In partnership with Microsoft, Paige has introduced Virchow2 and Virchow2G, the latest generation of its AI foundation models for...
Tempus AI’s Precision Oncology Study Unveils Validated Hla-Loh Assay
Tempus AI, a leading company in applying AI to precision medicine, has published a study validating its investigational human...
DeepCure’s Groundbreaking AI-Generated Drug DC-9476
DeepCure, a biotechnology company leveraging AI for drug discovery, has unveiled its first development candidate, DC-9476. This third-generation BRD...
Cybin Unveils Record Q1 Financials and Key Milestones
Cybin Inc., a clinical-stage neuropsychiatry company, reported its financial results for the first quarter ended June 30, 2024, and...
Merck Unveils Groundbreaking ESCC Trial Results: Unlocking New Hope for Patients
Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in...
Neurogene’s Triumphant Progress in NGN-401 Gene Therapy
Neurogene Inc. has made significant progress in its clinical-stage development of NGN-401 gene therapy for Rett syndrome. The therapy...